{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015936","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.187857+00:00","generated_at":"2026-06-15T09:30:36.703759+00:00","sec_items":["4.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivos Therapeutics cuts workforce 17%, accelerates cash flow positive target to Q1 2024","bullets":["Reduced workforce by approximately 17% as part of operational efficiency initiatives.","Now expects to achieve positive cash flow by Q1 2024, a full quarter earlier than prior mid-2024 guidance.","Revenues expected to be relatively flat sequentially in H1 2023, with growth acceleration starting Q3 2023.","Dismissed Plante & Moran as auditor; engaged Moss Adams LLP effective May 3, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015936","json":"https://secwatch.observer/filing/0001493152-23-015936.json","markdown":"https://secwatch.observer/filing/0001493152-23-015936.md","text":"https://secwatch.observer/filing/0001493152-23-015936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/0001493152-23-015936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:30:36.703759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f7dc9d1b9c41316ed8e9cb11c92d443785f5bfa","claim":"Vivos Therapeutics, Inc. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"ay 3, 2023, the Committee approved the engagement of Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm, effective immediately.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/0001493152-23-015936-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Moss Adams LLP"}],"fact_type":"auditor_change"},{"claim_id":"75c30ecea2f2232070d242eae6a9ca1f3024ce11","claim":"Vivos Therapeutics, Inc. dismissed Plante & Moran, PLLC as its auditor.","evidence_excerpt":"(the “ Company ”) dismissed Plante & Moran, PLLC (“ P&M ”), the Company’s independent registered public accounting firm, effective immediately.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/0001493152-23-015936-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Plante & Moran, PLLC"},{"label":"Successor","value":"Moss Adams LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}